James Gallagher, MD
Cardiovascular Disease · Rochester, NYNPI 1215078217
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,221 of the $3,215 with a category attached, or 69.1%. 6 manufacturers reported payments, led by Boston Scientific at 49.1% of the total.
Across 30 payments — averaging $107.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abbott$941
- Polynovo North America LLC$291
- Medtronic$211
- Biosense Webster, Inc.$119
- Urgo Medical North America, LLC$75
Across 5 payments — averaging $5617.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$28K
What the payments were for
- Travel & lodging$2,22169%
- Food & beverage$99531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $1,579 |
| Abbott | 9 | $941 |
| Polynovo North America LLC | 9 | $291 |
| Medtronic | 3 | $211 |
| Biosense Webster, Inc. | 1 | $119 |
| Urgo Medical North America, LLC | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$759
- Adapta$129
- Carto 3 System$119
- Carto Smarttouch$119
How this compares
$3,215 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $19,833 |
| SavaysaEdoxaban Tosylate | 11 | $4,693 |
| Metoprolol Succinate | 57 | $1,015 |
| Digoxin | 23 | $660 |
| Flecainide Acetate | 36 | $602 |
| Lisinopril | 19 | $63 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rochester
- James EichelbergerRochester$332K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.